000			02974cam a2200229 4500
001			NMDX7025
008			120401t2014 xxu||||| |||| 00| 0 eng d
100			_aSubbarao, S.
240			_aBMC Research Notes
245			_aCytomegalovirus proctitis mimicking rectal cancer in an immunocompetent elderly patient: a case report
260			_c2014
500			_aNMUH Staff Publications
500			_a15
520			_a<p style="margin: 0px 0px 0.5em; line-height: 1.538em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif;"><span style="font-size: 10pt;"><strong>BACKGROUND</strong>: Cytomegalovirus infection is associated with significant morbidity and mortality in immunocompromised patients, but its impact on immunocompetent patients is still poorly understood. Furthermore, there is increasing evidence implying that chronic infection may contribute to a heightened cardiovascular risk.</span></p><h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif;"><span style="font-size: 10pt;">CASE PRESENTATION:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 1.538em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif;"><span style="font-size: 10pt;">We describe the case of incidental diagnosis of Cytomegalovirus proctitis in an immune-competent white British elderly gentleman, admitted following a stroke and investigated for rectal cancer following the development of bloody diarrhoea and persistent systemic inflammatory response.</span></p><h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif;"><span style="font-size: 10pt;">CONCLUSION:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 1.538em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif;"><span style="font-size: 10pt;">This raised some several interesting points; firstly that we must revise our approach to investigating the immunocompetent elderly patient, secondly, could chronic Cytomegalovirus infection have contributed to the presentation of stroke in this patient and lastly what are the existing evidence for treatment in this population? We use this opportunity to try and address some of these questions and feel that this would be of benefit to the wider audience.We discuss the risk factors for disease in immune-competent patients and also a brief overview of the benefits of treatment in this population.</span></p>
700			_aO'Sullivan, A.
700			_aAdesina, T.
700			_aGwozdz, A.M.
700			_aRees, J.
700			_aSatta, G.
856			_uhttps://www.ncbi.nlm.nih.gov/pubmed/25399401
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242482/pdf/13104_2013_Article_3325.pdf
999			_c76036 _d76036